Every material Form 8-K IMMUCELL CORP /DE/ has filed with the SEC since July 09, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
ImmuCell Corporation reported preliminary, unaudited third-quarter 2026 total sales of $8.0 million, a 46.0% increase from the third quarter of 2025, and nine-month sales of $25.6 million, up 27.8%. The company said the comparison was aided in part by depressed third-quarter 2025 sales caused by high distributor purchases in the second quarter of 2025. Full financial results are due on a conference call on November 13, 2026, and the company will stop issuing early sales reports.
Q3 2026 total sales were $8.0 million, up 46.0%; domestic sales were $6.9 million, up 29.2%
Nine-month 2026 total sales were $25.6 million, up 27.8% from the nine months ended September 30, 2025
Q3 2025 comparison was depressed by high distributor purchases in Q2 2025
Full results will be discussed on a conference call on Friday, November 13, 2026, at 9:00 AM ET
ImmuCell reported unaudited results for the quarter ended June 30, 2026, with product sales up 11.5% to $7.2 million and net income of $1.8 million, or $0.20 per diluted share, versus $0.5 million, or $0.06 per basic share, a year earlier. Gross margin fell to 33.9% from 43.7%, and net income includes a one-time $2 million settlement payment from a former contract manufacturer.
Product sales rose 11.5% to approximately $7.2 million in Q2 2026, compared with the quarter ended June 30, 2025.
Gross margin declined to 33.9% of product sales from 43.7%, which the company attributed to lower manufacturing volumes, scrap from a quality issue with a purchased material, and shifted costs from the discontinued Re-Tain program.
Adjusted EBITDA was $2.7 million, compared with $1.4 million a year earlier; cash and cash equivalents rose to $8.9 million at June 30, 2026, from $3.8 million at December 31, 2025.
The company plans a capacity expansion of about $3.5 million (freeze-drying, first phase) and about $4.5 million (colostrum liquid processing, second phase), to be financed with cash on hand and cash from operations.
ImmuCell Corporation reported preliminary, unaudited product sales of $7.2 million for the quarter ended June 30, 2026, up 11.5% from $6.4 million a year earlier, with domestic sales up 27.7% and international sales down 38.9%. Sales for the six months ended June 30, 2026 were $17.5 million, up 20.9%. The figures are unaudited and do not include profit or guidance, and the company will discuss complete results on August 14, 2026.
Q2 2026 total product sales were $7.2 million, up 11.5% from $6.4 million in Q2 2025.
Domestic sales rose 27.7% to $6.2 million, while international sales fell $0.6 million, or 38.9%, to $1.0 million.
Six-month sales were $17.5 million, up 20.9% from $14.5 million in the first half of 2025.
Management will discuss complete results on a conference call on Friday, August 14, 2026 at 9:00 AM ET.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every IMMUCELL CORP /DE/ filing is on SEC EDGAR ↗. 8-K briefs of other companies →